PT  - JOURNAL ARTICLE
AU  - Meehan, Michael T.
AU  - Cocks, Daniel G.
AU  - Caldwell, Jamie M.
AU  - Trauer, James M.
AU  - Adekunle, Adeshina I.
AU  - Ragonnet, Romain R.
AU  - McBryde, Emma S.
TI  - Age-targeted dose allocation can halve COVID-19 vaccine requirements
AID  - 10.1101/2020.10.08.20208108
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.08.20208108
4099  - http://medrxiv.org/content/early/2020/12/02/2020.10.08.20208108.short
4100  - http://medrxiv.org/content/early/2020/12/02/2020.10.08.20208108.full
AB  - In anticipation of COVID-19 vaccine deployment, we use an age-structured mathematical model to investigate the benefits of optimizing age-specific dose allocation to suppress the transmission, morbidity and mortality of SARS-CoV-2 and the associated disease, COVID-19. To minimize transmission, we find that the highest priority individuals across 179 countries are typically those between 30 and 59 years of age because of their high contact rates and higher risk of infection and disease. Conversely, morbidity and mortality are initially most effectively reduced by targeting 60+ year olds who are more likely to experience severe disease. However, when population-level coverage is sufficient — such that herd immunity can be achieved through targeted dose allocation — prioritizing middle-aged individuals becomes the most effective strategy to minimize hospitalizations and deaths. For each metric considered, we show that optimizing the allocation of vaccine doses can more than double their effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.M. is funded by a postdoctoral research fellowship from the National Health and Medical Research Council's Centre of Research Excellence in Tuberculosis Control on Both Sides of Our Border (Project ID: 1153493).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll input data and model source code has been deposited in a recognized public source repository (GitHub, https://github.com/michaeltmeehan/covid19). https://github.com/michaeltmeehan/covid19